NCT03101111: A trial that was reported late by Themis Bioscience GmbH
This trial has reported, although it was 362 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03101111 |
|---|---|
| Title | Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in a Previously Epidemic Area |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 9, 2017 |
| Completion date | April 2, 2019 |
| Required reporting date | April 1, 2020, midnight |
| Actual reporting date | March 30, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 362 |